毒素在促进中风后患者实现目标的复杂作用
Miruna Ioana Săndulescu1,2,3,4, Delia Cinteză1,2,4, Daniela Poenaru1,2,4
1Doctoral School, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Toxins
|April 26, 2024
概括
这项研究发现,改善运动控制和先前的阿博托毒素A (BoNT-A) 注射可以预测中风后患者更好地实现功能目标. 这些发现增强了对中风相关的性和残疾的治疗管理.
科学领域:
- 神经学 神经学
- 康复医学 康复医学 康复医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 卒中幸存者经常经历和残疾,影响他们的生活质量.
- 有效管理中风后性对于功能恢复至关重要.
- 阿博托毒素A (BoNT-A) 是治疗的关键药理疗法.
研究的目的:
- 评估阿博托毒素A (BoNT-A) 对中风后患者目标实现量表 (GAS) 的影响.
- 为了确定与BoNT-A治疗后功能目标实现相关的因素.
- 量化性,疼痛和运动控制的改善.
主要方法:
- 在52名中风后患者中进行的观察性非随机临床研究.
- 治疗包括BoNT-A对上肢的焦点治疗和康复计划.
- 目标实现量表 (GAS),修改的阿什沃思量表 (MAS),数值评分量表 (NRS) 和被动运动范围 (p-ROM) 的评估.
主要成果:
- 改善的运动控制和更多的先前BoNT-A注射是实现GAS-T得分的独立预测因素.
- 靠近,中间和手腕运动控制的改善与GAS分数的显著改善相关.
- 与右侧缺陷相比,左侧运动缺陷的患者在GAS-T得分上表现出更大的改善.
结论:
- BoNT-A治疗对中风后动的目标实现量表得分产生积极影响.
- 改善运动控制和先前的BoNT-A治疗是实现功能目标的关键因素.
- 结合康复,BoNT-A通过减少疼痛和性来增强四肢的移动性.
关键词:
目标实现规模 目标实现规模修改的-阿什沃思尺度-阿什沃思尺度数字评级级的数值级别.阿博托毒素-A-A的使用.被动的运动范围.性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性等.一次性中风中风中风中风中风更多相关视频
14:56The Combined Use of Transcranial Direct Current Stimulation and Robotic Therapy for the Upper Limb
Published on: September 23, 2018
9.0K
15:00The Impact of Motor Task Conditions on Goal-Directed Arm Reaching Kinematics and Trunk Compensation in Chronic Stroke Survivors
Published on: May 2, 2021
3.5K
相关概念视频
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
674
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
674
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
662
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
662
Skeletal Muscle Relaxants: Therapeutic Uses
482
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
482
Long-term Potentiation
55.2K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
55.2K
